BMS-986166

DRUG7 trials

Sponsors

Bristol-Myers Squibb

Conditions

Dermatitis, AtopicHealthyHealthy ParticipantsHealthy VolunteersUlcerative Colitis

Phase 1

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

CompletedNCT02790125

Bristol-Myers SquibbHealthy

Start: 2016-07-28End: 2017-11-07Target: 66Updated: 2017-11-24

A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers

CompletedNCT03038711

Bristol-Myers SquibbUlcerative Colitis

Start: 2017-02-01End: 2017-08-10Updated: 2019-01-30

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

CompletedNCT04934696

Bristol-Myers SquibbHealthy Participants

Start: 2021-08-03End: 2022-01-25Updated: 2022-03-18

A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants

CompletedNCT04956627

Bristol-Myers SquibbHealthy Participants

Start: 2021-07-28End: 2022-04-27Updated: 2022-05-13

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese Participants

CompletedNCT04965402

Bristol-Myers SquibbHealthy Volunteers

Start: 2021-07-15End: 2022-02-07Updated: 2022-03-09

A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants

CompletedNCT05409157

Bristol-Myers SquibbHealthy Participants

Start: 2022-06-17End: 2022-10-15Updated: 2023-03-22

Phase 2

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

CompletedNCT05014438

Bristol-Myers SquibbDermatitis, Atopic

Start: 2021-08-17End: 2022-08-22Updated: 2023-10-18

Related Papers

The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants

Expert Opinion on Investigational Drugs2020-04-024 citations